Unlike this complex role of CXCR3 signaling in the context of CRC disease, which apparently can directly influence tumor cell behavior in addition to immune cell recruitment, chemokine receptors with a more restricted expression pattern limited to specific types of immune cells may represent more favorable therapeutic targets, in the sense that their effect on the fate of tumor development can be more precisely predicted. This evidence concerns the gene CXCR3 and colorectal carcinoma.